
============================================================
ðŸ“Š FINAL CONSENSUS ANALYSIS - Article 2
============================================================
Timestamp: 2025-06-23 19:00:15
Headline Summary: Small biotech CureGen soars on FDA approval, analysts remain skeptical
Key Highlights: FDA approval for novel cancer treatment, analyst skepticism lingered despite approval
Final Sentiment: Negative
Confidence: 70%
Impact Magnitude: Low
Agreement Level: Strong
Rounds to Consensus: 5

Rationale: risk_analyst: The FDA approval for CureGen\u2019s novel cancer treatment is a positive development, but analyst skepticism about its long-term effectiveness and potential side effects warrants a more cautious approach. The significance of addressing unaddressed risks should temper expectations and warrant a Negative sentiment. I decrease confidence due to the importance of evaluating these risks. growth_analyst: The FDA approval for CureGenâ€™s novel cancer treatment is a positive development but analyst skepticism about its long-term effectiveness and potential side effects warrants a more cautious approach. The current impact magnitude of Medium seems too high considering the lingering concerns, which can potentially temper expectations. sentiment_analyst: The FDA approval for CureGen's novel cancer treatment is a positive development, but analyst skepticism about its long-term effectiveness and potential side effects warrants a more cautious approach. The current impact magnitude of Medium seems too high considering the lingering concerns, which can potentially temper expectations. My proposed sentiment reflects this caution.

Discussion Summary: Discussion involved 5 rounds. Consensus reached with 3/3 agents agreeing on Negative sentiment.
============================================================
